The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum

Clinical Epigenetics

Shiva M Singh³  Richard O’Reilly²  Nagalingam Rajakumar²  Christina A Castellani¹  Patrick McDonald¹  Benjamin I Laufer¹  Melkaye G Melka¹ 

[1] Molecular Genetics Unit, Department of Biology, The University of Western Ontario, London, ON N6A 5B7, Canada;Department of Psychiatry, The University of Western Ontario, London, ON N6A 5B7, Canada;Children's Health Research Institute, 800 Commissioners Road East, London, ON N6C 2V5, Canada

关键词: Rat;    Psychosis;    DNA methylation;    Cerebellum;    Hippocampus;    Epigenetic;   

Others  :  790647
DOI  :  10.1186/1868-7083-6-1

 received in 2013-08-29, accepted in 2013-12-04,  发布年份 2014

【 摘 要 】

Background

The mechanism of action of olanzapine in treating schizophrenia is not clear. This research reports the effects of a therapeutic equivalent treatment of olanzapine on DNA methylation in a rat model in vivo.

Genome-wide DNA methylation was assessed using a MeDIP-chip analysis. All methylated DNA immunoprecipitation (MeDIP), sample labelling, hybridization and processing were performed by Arraystar Inc (Rockville, MD, USA). The identified gene promoters showing significant alterations to DNA methylation were then subjected to Ingenuity Pathway Analysis (Ingenuity System Inc, CA, USA).

Results

The results show that olanzapine causes an increase in methylation in 1,140, 1,294 and 1,313 genes and a decrease in methylation in 633, 565 and 532 genes in the hippocampus, cerebellum and liver, respectively. Most genes affected are tissue specific. Only 41 affected genes (approximately 3%) showed an increase and no gene showed a decrease in methylation in all three tissues. Further, the two brain regions shared 123 affected genes (approximately 10%). The affected genes are enriched in pathways affecting dopamine signalling, molecular transport, nervous system development and functions in the hippocampus; ephrin receptor signalling and synaptic long-term potentiation in the cerebellum; and tissue morphology, cellular assembly and organization in the liver. Also, the affected genes included those previously implicated in psychosis.

Conclusions

The known functions of affected genes suggest that the observed epigenetic changes may underlie the amelioration of symptoms as well as accounting for certain adverse effects including the metabolic syndrome. The results give insights into the mechanism of action of olanzapine, therapeutic effects and the side effects of antipsychotics.

【 授权许可】

   
2014 Melka et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]van Os J, Kapur S: Schizophrenia. Lancet. 2009, 374:635-644.
• [2]Fitzgerald PB, Benitez J, Daskalakis JZ, De Castella A, Kulkarni J: The treatment of recurring auditory hallucinations in schizophrenia with rTMS. World J Biol Psychiatry 2006, 7:119-122.
• [3]Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963, 20:140-144.
• [4]Kane JM: The current status of neuroleptic therapy. J Clin Psychiatry 1989, 50:322-328.
• [5]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
• [6]Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B: Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: results from the ESCAPE study. NS Drugs 2012, 26:975-982.
• [7]Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ: Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 2012, 17:242-266.
• [8]Muller DJ, Muglia P, Fortune T, Kennedy JL: Pharmacogeneticsof antipsychotic-induced weight gain. Pharmacol Res 2004, 49:309-312.
• [9]Muller DJ, Kennedy JL: Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006, 7:863-887.
• [10]Lencz T, Malhotra AK: Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 2009, 11:405-411.
• [11]Jasovic-Gasic M, Vukovic O, Pantovic M, Cvetic T, Maric-Bojovic N: Antipsychotics – history of development and field of indication, new wine – old glasses. Psychiatr Danub 2012, 24(Suppl 3):S342-S344.
• [12]van Rossum JM: The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966, 160:492-494.
• [13]Manschreck TC, Boshes RA: The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007, 15:245-258.
• [14]Razin A, Kantor B: DNA methylation in epigenetic control of gene expression. Prog Mol Subcell Biol 2005, 38:151-167.
• [15]Grace AA: Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 2012, 62:1342-1348.
• [16]Clark SL, Adkins DE, van den Oord EJ: Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr Res 2011, 132:114-120.
• [17]Dratcu L, Grandison A, McKay G, Bamidele A, Vasudevan V: Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am J Ther 2007, 14:314-318.
• [18]Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M: Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: Validation and reproducibility. J Cereb Blood Flow Metab 2000, 20:225-243.
• [19]Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull 2009, 35:549-562.
• [20]Kelkar A, Deobagkar D: A novel method to assess the full genome methylation profile using monoclonal antibody combined with the high throughput based microarray approach. Epigenetics 2009, 4:415-420.
• [21]Razin A, Cedar H: DNA methylation and gene expression. Microbiol Rev 1991, 55:451-822.
• [22]Bredberg A, Bodmer W: Cytostatic drug treatment causes seeding of gene promoter methylation. Eur J Cancer 2007, 43:947-954.
• [23]Szyf M: Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol 2010, 39:62-77.
• [24]Melas PA, Rogdaki M, Osby U, Schalling M, Lavebratt C, Ekstrom TJ: Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J 2012, 26:2712-2718.
• [25]Kunii Y, Hyde TM, Ye T, Li C, Kolachana B, Dickinson D, Weinberger DR, Kleinman JE, Lipska BK: Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. Mol Psychiatry 2013. doi:10.1038/mp.2012.174
• [26]Bromberg A, Levine J, Nemetz B, Belmaker RH, Agam G: No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res 2008, 101:50-57.
• [27]Bardgett ME, Humphrey WM, Csernansky JG: The effects of excitotoxic hippocampal lesions in rats on risperidone- and olanzapine-induced locomotor suppression. Neuro Psychopharmacol 2002, 27:930-938.
• [28]Geyer MA, Krebs-Thomson K, Braf DL, Swerdlow NR: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
• [29]Deng C, Lian J, Pai N, Huang XF: Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol 2012, 26:1271-1279.
• [30]Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, Theodoropoulou P, Fernández LG, Uçok A, Tessier C, Bergmans P, Hoeben D: Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol 2012, 32:449-457.
• [31]Shrivastava A, Johnston M, Terpstra K, Stitt L, Shah N: Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia. Indian J Psychiatry 2012, 54:248-252.
• [32]Gray R: Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia. Ment Health Care 1998, 1:193-194.
• [33]Feng W, Dong Z, He B, Wang K: Analysis method of epigenetic DNA methylation to dynamically investigate the functional activity of transcription factors in gene expression. BMC Genomics 2012, 13:532. BioMed Central Full Text
• [34]Dong E, Grayson DR, Guidotti A, Costa E: Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics 2009, 1:201-211.
• [35]Ereshefsky L, Riesenman C, Lam YW: Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996, 57(Suppl 8):17-24.
• [36]Gray SG, Eriksson T, Ekstrom TJ: Methylation, gene expression and the chromatin connection in cancer (review). Int J Mol Med 1999, 4:333-350.
• [37]Numata S, Ye T, Hyde TM, Guitart-Navarro X, Tao R, Wininger M, Colantuoni C, Weinberger DR, Kleinman JE, Lipska BK: DNA methylation signatures in development and aging of the human prefrontal cortex. Am J Hum Genet 2012, 90:260-272.
• [38]Jun H, HussainiS MQ, Rigby MJ, Jang MH: Functional role of adult hippocampal neurogenesis as a therapeutic strategy for mental disorders. Neural Plast 2012, 2012:854285.
• [39]Eisenberg DP, Ianni AM, Wei SM, Kohn PD, Kolachana B, Apud J, Weinberger DR, Berman KF: Brain-derived neurotrophic factor (BDNF) val(66)met polymorphism differentially predicts hippocampal function in medication-free patients with schizophrenia. J Neuropsych Clin Neurosci 2009, 21:30-37.
• [40]Lorincz MC, Dickerson DR, Schmitt M, Groudine M: Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol 2004, 11:1068-1075.
• [41]Oh YS, Gao P, Lee KW, Ceglia I, Seo JS, Zhang X, Ahn JH, Chait BT, Patel DJ, Kim Y, Greengard P: SMARCA3, a chromatin-remodeling factor, is required for p11-dependent antidepressant action. Cell 2013, 152:831-843.
• [42]Santini MA, Ratner C, Aznar S, Klein AB, Knudsen GM, Mikkelsen JD: Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia. J Neurosci Res 2013, 91(5):634-641.
• [43]Olszewski M, Piasecka J, Goda SA, Kasicki S, Hunt MJ: Antipsychotic compounds differentially modulate high-frequency oscillations in the rat nucleus accumbens: a comparison of first- and second-generation drugs. Int J Neuropsychopharmacol 2012, 16:1009-20.
• [44]Svenningson P, Nishi A, Fisone G, Girault J, Nairn AC, Greengard P: DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 2004, 44:269-296.
• [45]Ginovart N, Kapur S: Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012, 212:27-52.
• [46]Albert KA, Hemmings HC Jr, Adamo AI, Potkin SG, Akbarian S, Sandman CA, Cotman CW, Bunney WE Jr, Greengard P: Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 2002, 59:705-712.
• [47]Li C, Zheng Y, Qin W, Tao R, Pan Y, Xu Y, Li X, Gu N, Feng G, He L: A family-based association study of kinesin heavy chain member 2 gene (KIF2) and schizophrenia. NeurosciLett 2006, 407:151-155.
• [48]Petronis A, Gottesman II, Kan P, Kennedy JL, Basile VS, Paterson AD, Popendikyte V: Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull 2003, 29:169-178.
• [49]Ide M, Lewis DA: Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. Biol Psychiatry 2010, 68:25-32.
• [50]Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
• [51]Shimizu H, Iwayama Y, Yamada K, Toyota T, Minabe Y, Nakamura K, Nakajima M, Hattori E, Mori N, Osumi N, Yoshikawa T: Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia. Schizophr Res 2006, 84:244-252.
• [52]Ho BC, Milev P, O’Leary DS, Librant A, Andreasen NC, Wassink TH: Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006, 63:731-740.
• [53]Maziade M, Martinez M, Rodrigue C, Gauthier B, Tremblay G, Fournier C, Bissonnette L, Simard C, Roy MA, Rouillard E, Mérette C: Childhood/early adolescence-onset and adult-onset schizophrenia. Heterogeneity at the dopamine D3 receptor gene. Br J Psychiatry 1997, 170:27-30.
• [54]Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A: DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia. Mol Biol Rep 2012, 39:10889-10893.
• [55]Klein R: Bidirectional modulation of synaptic functions by eph/ephrin signaling. Nat Neurosci 2009, 12:15-20.
• [56]Senturk A, Pfennig S, Weiss A, Burk K, Acker-Palmer A: EphrinBsare essential components of the Reelin pathway to regulate neuronal migration. Nature 2011, 472:356-360.
• [57]Iwamoto S, Suzuki T, Sutani A, Kuraki T, Isobe T: A case of atypical drug-induced hypersensitivity syndrome caused by isoniazid. Kekkaku 2012, 87:777-782.
• [58]Zhang D, Cheng L, Badner JA, Chen C, Chen Q, Luo W, Craig DW, Redman M, Gershon ES, Liu C: Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet 2010, 86:411-419.
• [59]Armano S, Rossi P, Taglietti V, D’Angelo E: Long-term potentiation of intrinsic excitability at the mossy fiber-granule cell synapse of rat cerebellum. J Neurosci 2000, 20:5208-5216.
• [60]Aizenman CD, Linden DJ: Rapid, synaptically driven increases in the intrinsic excitability of cerebellar deep nuclear neurons. Nat Neurosci 2000, 3:109-111.
• [61]Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, Heshmati M, Golden SA, Kennedy PJ, Takahashi N, Dietz DM, Mocci G, Gabilondo AM, Hanks J, Umali A, Callado LF, Gallitano AL, Neve RL, Shen L, Buxbaum JD, Han MH, Nestler EJ, Meana JJ, Russo SJ, González-Maeso J: HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012, 15:1245-1254.
• [62]Huang Y, Kang BN, Tian J, Liu Y, Luo HR, Hester L, Snyder SH: The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycinm TOR pathway. J Neurosci 2007, 27:449-458.
• [63]Abdolmaleky HM, Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, Tsuang MT: Methylomics in psychiatry: modulation of gene–environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet 2004, 127B:51-59.
• [64]Dong E, Nelson M, Grayson DR, Costa E, Guidotti A: Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci USA 2008, 105:13614-13619.
• [65]Minet-Ringuet J, Even PC, Valet P, Carpéné C, Visentin V, Prévot D, Daviaud D, Quignard-Boulange A, Tomé D, de Beaurepaire R: Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 2007, 12:562-571.
• [66]Zhang K, Huang XZ, Li XN, Feng M, Li L, Cai XJ, et al.: Interleukin 6 destabilizes atherosclerotic plaques by downregulating prolyl-4-hydroxylase alpha1 via a mitogen-activated protein kinase and c-jun pathway. Arch Biochem Biophys 2012, 528:127-133.
• [67]Pijet M, Pijet B, Litwiniuk A, Pajak B, Gajkowska B, Orzechowski A: Leptin impairs myogenesis in C2C12 cells through JAK/STAT and MEK signaling pathways. Cytokine 2013, 61:445-54.
• [68]Mir A, Shivakumar K, Williamson RJ, McAllister V, O’Keane V, Aitchison KJ: Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008, 22:244-253.
• [69]Scornaiencki R, Cantrup R, Rushlow WJ, Rajakumar N: Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness. Int J Neuropsychopharmacol 2009, 12:1195-2208.
• [70]Pirooznia M, Nagarajan V, Deng Y: GeneVenn - a web application for comparing gene lists using Venn diagrams. Bioinformation 2007, 1:420-422.
• [71]Ingenuity pathway analysis http://www.ingenuity.com/ webcite